GB01-VA-PL2202, a Claudin-6-targeting ADC with potent antitumor efficacy and bystander killing activity
May 7, 2024
Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
